Effects of the proteasome inhibitor bortezomib in combination with chemotherapy for the treatment of mantle cell lymphoma: a meta-analysis
The efficacy and safety of bortezomib-based chemotherapy were characterized in mantle cell lymphoma (MCL) patients. The PubMed, the Cochrane Library, Clinical Key, Science Direct, Oxford Journals, and the China National Knowledge Internet databases were searched up to 01 May 2019. The selected trials must match the inclusion criteria and be carried out quality appraisal and synthesis at efficacy and safety. The enrolled MCL patients using bortezomib-based chemotherapy or chemotherapy alone must be compared. The overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) were combined to evaluate the efficacy and the serious adverse events (SAEs) (grade III-IV peripheral neuropathy, neutropenia and infection) were used to evaluate the safety. The heterogeneity of the result was analyzed simultaneously. A total of 620 patients were enrolled across four studies in our meta-analysis, and the pooled results showed that the PFS (HR: 0.66, 95% CI: 0.54-0.82; p=0.0001) and OS (HR: 0.73, 95% CI: 0.55-0.96; p=0.03) of patients with bortezomib-based chemotherapy were better than that of patients with chemotherapy alone except ORR (RR : 1.46, 95% CI: 0.85-2.49; P=0.17), while SAEs were prominent in the combination group. MCL patients who are ineligible for transplant or high-dose chemotherapy could benefit from bortezomib-based chemotherapy.